Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 9/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097335 | 0.85 | MAPK13 (0.54) | MAPK13MAPK12MAPK11MAPK14KMT2A | |
| SCHEMBL6094765 | 0.83 | MAPK14 (0.61) | MAPK13MAPK12MAPK11MAPK14RAB9A | |
| SCHEMBL6099284 | 0.79 | MAPK14 (0.63) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6097278 | 0.79 | MAPK14 (0.63) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6633835 | 0.78 | MAPK14 (0.57) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6096703 | 0.78 | MAPK14 (0.63) | MAPK13MAPK12MAPK11MAPK14KMT2A | |
| SCHEMBL6096253 | 0.77 | MAPK14 (0.60) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6097137 | 0.77 | MAPK14 (0.71) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6093762 | 0.77 | MAPK14 (0.74) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6094353 | 0.76 | MAPK14 (0.59) | MAPK13MAPK12MAPK11MAPK14RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | claimed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| EP-1423356-A2 | NOVEL AMINOBENZOEPHENONES | Leo Pharma A/S (DK) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
| WO-2003018535-A2 | NOVEL AMINOBENZOEPHENONES | LEO PHARMA A/S (DK) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | MAPK13 2918/4885MAPK12 2155/4885MAPK11 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.